Moberg Pharma AB (OSTO:MOB) Cyclically Adjusted Revenue per Share: kr62.70 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MOB Moberg Pharma AB OSTO:MOB
59 GF Score
Price kr9.27
GF Value kr12.45
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB Cyclically Adjusted Revenue per Share?

Moberg Pharma AB OSTO:MOB -0.32% 59 Cyclically Adjusted Revenue per Share is kr62.70 as of Mar. 2026. GuruFocus rates OSTO:MOB with a GF Score™ of 59/100 and a GF Value™ of kr12.45 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Moberg Pharma AB's adjusted revenue per share for the three months ended in Mar. 2026 was kr0.103. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr62.70 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Moberg Pharma AB's average Cyclically Adjusted Revenue Growth Rate was -27.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-22), Moberg Pharma AB's current stock price is kr9.27. Moberg Pharma AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr62.70. Moberg Pharma AB's Cyclically Adjusted PS Ratio of today is 0.15.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Moberg Pharma AB was 6.03. The lowest was 0.08. And the median was 0.15.


Moberg Pharma AB  (OSTO:MOB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Moberg Pharma AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=9.27/62.70
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Moberg Pharma AB was 6.03. The lowest was 0.08. And the median was 0.15.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Moberg Pharma AB Cyclically Adjusted Revenue per Share Related Terms


Moberg Pharma AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB Cyclically Adjusted Revenue per Share Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 91.47

Moberg Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 86.89 83.10 76.60 68.46 62.70

OSTO:MOB vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Cyclically Adjusted PS Ratio falls into.


OSTO:MOB
59GF Score
Moberg Pharma AB OSTO:MOB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moberg Pharma AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Moberg Pharma AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.103/133.5600*133.5600
=0.103

Current CPI (Mar. 2026) = 133.5600.

Moberg Pharma AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 20.659 100.276 27.516
201603 27.473 100.751 36.419
201606 28.393 101.019 37.539
201609 41.193 101.138 54.399
201612 34.157 102.022 44.716
201703 33.780 102.022 44.223
201706 44.165 102.752 57.407
201709 35.307 103.279 45.659
201712 29.375 103.793 37.800
201803 0.000 103.962 0.000
201806 46.291 104.875 58.953
201809 35.211 105.679 44.501
201812 -109.589 105.912 -138.197
201903 5.017 105.886 6.328
201906 0.000 106.742 0.000
201909 14.668 107.214 18.272
202003 0.000 106.563 0.000
202006 0.000 107.498 0.000
202009 0.000 107.635 0.000
202103 0.000 108.360 0.000
202106 0.000 108.928 0.000
202109 0.000 110.338 0.000
202112 0.000 112.486 0.000
202203 0.000 114.825 0.000
202206 0.000 118.384 0.000
202209 0.014 122.296 0.015
202212 0.000 126.365 0.000
202303 0.000 127.042 0.000
202306 0.000 129.407 0.000
202309 0.000 130.224 0.000
202312 0.000 131.912 0.000
202403 0.017 132.205 0.017
202406 0.132 132.716 0.133
202409 0.081 132.304 0.082
202412 0.022 132.987 0.022
202503 0.081 132.825 0.081
202506 0.075 133.699 0.075
202509 0.083 133.480 0.083
202512 0.043 133.390 0.043
202603 0.103 133.560 0.103

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr62.70 mean?
Moberg Pharma AB (OSTO:MOB) has a Cyclically Adjusted Revenue per Share of kr62.70 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Moberg Pharma AB and its competitors.
Is Moberg Pharma AB's Cyclically Adjusted Revenue per Share too high?
Moberg Pharma AB's current Cyclically Adjusted Revenue per Share is kr62.70. Overall, Moberg Pharma AB has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Moberg Pharma AB's Cyclically Adjusted Revenue per Share of kr62.70 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Moberg Pharma AB and its competitors. Moberg Pharma AB's current Cyclically Adjusted Revenue per Share is kr62.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Moberg Pharma AB (OSTO:MOB) is currently considered Modestly Undervalued. The stock's GF Value™ is kr12.45, compared to a current price of kr9.27 — trading 25.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr62.70. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Moberg Pharma AB (OSTO:MOB), the current Cyclically Adjusted Revenue per Share is kr62.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (OSTO:MOB) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of kr9.27 is trading 25.5% below its estimated GF Value™ of kr12.45. GuruFocus considers Moberg Pharma AB to be Modestly Undervalued.

Key valuation signals for OSTO:MOB:

  • Cyclically Adjusted Revenue per Share: kr62.70
  • GF Value™: kr12.45 vs. price of kr9.27 (25.5% below fair value)
  • GF Score™: 59/100 with 1 warning sign

No single metric tells the full story. See the OSTO:MOB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Moberg Pharma AB Business Description

Other Exchanges MBGPF:USA
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score

Get the complete analysis for OSTO:MOB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr9.27
Price
kr12.45
GF Value